WO2018117462A3 - 신규한 비브리오 파라헤몰리티쿠스 박테리오파지 Ｖｉｂ-ＰＡＰ-4 및 이의 비브리오 파라헤몰리티쿠스 균 증식 억제 용도 - Google Patents

신규한 비브리오 파라헤몰리티쿠스 박테리오파지 Ｖｉｂ-ＰＡＰ-4 및 이의 비브리오 파라헤몰리티쿠스 균 증식 억제 용도 Download PDF

Info

Publication number
WO2018117462A3
WO2018117462A3 PCT/KR2017/013765 KR2017013765W WO2018117462A3 WO 2018117462 A3 WO2018117462 A3 WO 2018117462A3 KR 2017013765 W KR2017013765 W KR 2017013765W WO 2018117462 A3 WO2018117462 A3 WO 2018117462A3
Authority
WO
WIPO (PCT)
Prior art keywords
vibrio
bacteria
pap
vibrio parahaemolyticus
parahaemoliticus
Prior art date
Application number
PCT/KR2017/013765
Other languages
English (en)
French (fr)
Other versions
WO2018117462A2 (ko
Inventor
윤성준
전수연
권안성
송현민
황순혜
강상현
Original Assignee
주식회사 인트론바이오테크놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 인트론바이오테크놀로지 filed Critical 주식회사 인트론바이오테크놀로지
Priority to US16/471,051 priority Critical patent/US11679137B2/en
Priority to CN201780079660.5A priority patent/CN110214181A/zh
Publication of WO2018117462A2 publication Critical patent/WO2018117462A2/ko
Publication of WO2018117462A3 publication Critical patent/WO2018117462A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Birds (AREA)
  • Insects & Arthropods (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

본 발명은 비브리오 파라헤몰리티쿠스 균을 특이적으로 사멸시킬 수 있는 능력을 갖고 서열번호 1로 표시되는 유전체를 갖는 것을 특징으로 하는 자연으로부터 분리한 미오비리대 박테리오파지 Vib-PAP-4(수탁번호 KCTC 13168BP), 및 이를 유효성분으로 포함하는 조성물을 이용한 비브리오 파라헤몰리티쿠스 균의 감염을 방지 및 비브리오 파라헤몰리티쿠스 균의 감염을 치료하는 방법에 관한 것이다.
PCT/KR2017/013765 2016-12-21 2017-11-29 신규한 비브리오 파라헤몰리티쿠스 박테리오파지 Ｖｉｂ-ＰＡＰ-4 및 이의 비브리오 파라헤몰리티쿠스 균 증식 억제 용도 WO2018117462A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/471,051 US11679137B2 (en) 2016-12-21 2017-11-29 Vibrio parahaemolyticus bacteriophage Vib-PAP-4 and use thereof in inhibiting proliferation of Vibrio parahaemoliticus bacteria
CN201780079660.5A CN110214181A (zh) 2016-12-21 2017-11-29 新型副溶血弧菌噬菌体vib-pap-4及其用于抑制副溶血弧菌细菌增殖的用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0175223 2016-12-21
KR1020160175223A KR20180072055A (ko) 2016-12-21 2016-12-21 신규한 비브리오 파라헤몰리티쿠스 박테리오파지 Ｖｉｂ-ＰＡＰ-4 및 이의 비브리오 파라헤몰리티쿠스 균 증식 억제 용도

Publications (2)

Publication Number Publication Date
WO2018117462A2 WO2018117462A2 (ko) 2018-06-28
WO2018117462A3 true WO2018117462A3 (ko) 2019-01-24

Family

ID=62627516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/013765 WO2018117462A2 (ko) 2016-12-21 2017-11-29 신규한 비브리오 파라헤몰리티쿠스 박테리오파지 Ｖｉｂ-ＰＡＰ-4 및 이의 비브리오 파라헤몰리티쿠스 균 증식 억제 용도

Country Status (4)

Country Link
US (1) US11679137B2 (ko)
KR (1) KR20180072055A (ko)
CN (1) CN110214181A (ko)
WO (1) WO2018117462A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101915486B1 (ko) * 2017-05-10 2018-11-08 주식회사 인트론바이오테크놀로지 신규한 비브리오 파라헤몰리티쿠스 박테리오파지 Vib-PAP-7 및 이의 비브리오 파라헤몰리티쿠스 균 증식 억제 용도
CN114672467A (zh) * 2022-04-11 2022-06-28 扬州大学 一种防治凡纳滨对虾副溶血弧菌的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130021677A (ko) * 2011-08-23 2013-03-06 경희대학교 산학협력단 식중독을 유발하는 살모넬라에 특이적 사멸능을 갖는 박테리오파지
KR20140000541A (ko) * 2012-06-25 2014-01-03 주식회사 씨티씨바이오 신규한 박테리오파지 ｐｖｐ-1 및 이의 비브리오 파라헤몰리티쿠스 증식 억제 용도
KR20150024115A (ko) * 2013-08-26 2015-03-06 군산대학교산학협력단 바실러스 서브틸러스 및 파지 혼합물을 유효성분으로 함유하는 어류용 프로바이오틱스 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101798568B (zh) * 2009-04-03 2012-06-20 珠海市晋平科技有限公司 一种分离的副溶血弧菌噬菌体及其在杀菌和防菌中的应用
US9504721B2 (en) 2012-06-04 2016-11-29 Ctc Bio, Inc. Bacteriophage and its use for preventing proliferation of pathogenic bacteria
WO2013191363A1 (ko) * 2012-06-22 2013-12-27 주식회사 씨티씨바이오 신규한 박테리오파지 및 병원성 박테리아 증식 억제 용도
KR101592175B1 (ko) * 2014-04-29 2016-02-05 주식회사 인트론바이오테크놀로지 스트렙토코커스 파라우베리스 감염을 방지 및 처치하는 방법
KR101727456B1 (ko) * 2015-12-21 2017-04-17 주식회사 인트론바이오테크놀로지 신규한 비브리오 파라헤몰리티쿠스 박테리오파지 Ｖｉｂ-ＰＡＰ-1 및 이의 비브리오 파라헤몰리티쿠스 균 증식 억제 용도
KR101915486B1 (ko) * 2017-05-10 2018-11-08 주식회사 인트론바이오테크놀로지 신규한 비브리오 파라헤몰리티쿠스 박테리오파지 Vib-PAP-7 및 이의 비브리오 파라헤몰리티쿠스 균 증식 억제 용도
CN112760296B (zh) * 2021-01-29 2022-06-17 青岛润达生物科技有限公司 一株副溶血弧菌噬菌体rdp-vp-19010及其应用
CN113368221A (zh) * 2021-06-21 2021-09-10 南京北极光生物科技有限公司 一种组合物、制备方法及其在治疗细菌性疾病中的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130021677A (ko) * 2011-08-23 2013-03-06 경희대학교 산학협력단 식중독을 유발하는 살모넬라에 특이적 사멸능을 갖는 박테리오파지
KR20140000541A (ko) * 2012-06-25 2014-01-03 주식회사 씨티씨바이오 신규한 박테리오파지 ｐｖｐ-1 및 이의 비브리오 파라헤몰리티쿠스 증식 억제 용도
KR20150024115A (ko) * 2013-08-26 2015-03-06 군산대학교산학협력단 바실러스 서브틸러스 및 파지 혼합물을 유효성분으로 함유하는 어류용 프로바이오틱스 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALANIS VILLA, A. ET AL.: "Genome Sequence of Temperate Vibrio Parahaemolyticus Bacteriophage vB VpaS MARIO", JOURNAL OF VIROLOGY, vol. 86, no. 24, December 2012 (2012-12-01), pages 13851 - 13852 *
JUN, J. W. ET AL.: "Bacteriophage Therapy of a Vibrio Parahaemolyticus Infection Caused by a Multiple-antibiotic-resistant 03:K6 Pandemic Clinical Strain", J. INFECT. DIS., vol. 210, no. 1, 1 July 2014 (2014-07-01), pages 72 - 78, XP055245527 *

Also Published As

Publication number Publication date
KR20180072055A (ko) 2018-06-29
US11679137B2 (en) 2023-06-20
CN110214181A (zh) 2019-09-06
WO2018117462A2 (ko) 2018-06-28
US20190328803A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
MX2017008561A (es) Novedoso bacteriófago clo-pep-1 de clostridium perfringens y su uso para inhibir la proliferación de clostridium perfringens.
MX2017008563A (es) Novedoso bacteriófago esc-cop-1 de e. coli tipo f18 productora de toxina shiga y su uso para inhibir la proliferación de e. coli tipo f18 productora de toxina shiga.
MX2017008562A (es) Novedoso bacteriófago de e. coli enteroinvasiva esc-cop-4 y su uso para inhibir la proliferación de e. coli enteroinvasiva.
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
PH12016501254A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
MX2019002978A (es) Composiciones que comprenden una bacteria no patogena y metodos para proteger plantas y animales anfitriones contra enfermedades micoticas, bacterianas y virales.
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
MX2019009964A (es) Nuevo bacteriofago de clostridium perfringens clo-pep-2 y uso para inhibir la proliferacion de clostridium perfringens.
MX2016014807A (es) Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados.
NZ708928A (en) Mannose derivatives for treating bacterial infections
BR112018012044A2 (pt) bacteriófago pas-mup-1 de pasteurella multocida inovador e uso do mesmo para inibir a proliferação de pasteurella multocida
MX2023000736A (es) Productos microbianos alimentados en directo.
MX2020006191A (es) Bacteriocinas terapeuticas.
NZ735648A (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2017012073A (es) Compuestos de minociclina para biodefensas.
WO2018155813A3 (ko) 엔테로코쿠스 패슘에 대하여 용균력을 가지는 신규한 항균단백질 efal-2
MX2022016066A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
PH12016502001A1 (en) Novel bacteriophage and composition comprising same
WO2019235782A8 (ko) 신규한 스트렙토코커스 수이스 박테리오파지 str-sup-2 및 이의 스트렙토코커스 수이스 균 증식 억제 용도
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
WO2018117462A3 (ko) 신규한 비브리오 파라헤몰리티쿠스 박테리오파지 Ｖｉｂ-ＰＡＰ-4 및 이의 비브리오 파라헤몰리티쿠스 균 증식 억제 용도
MX2021003598A (es) Microorganismos para la inhibicion de patogenos vegetales.
WO2019039781A3 (ko) 신규한 에로모나스 살모니시다 박테리오파지 ａｅｒ-ｓａｐ-2 및 이의 에로모나스 살모니시다 균 증식 억제 용도
WO2011155727A3 (ko) 살모넬라 콜레라수이스 또는 살모넬라 두블린 감염을 방지 및 처치하는 방법
MX2020008677A (es) Novedoso bacteriofago de salmonella heidelberg sal-hep-1 y su uso para inhibir el crecimiento de las bacterias de salmonella heidelberg.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17882903

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17882903

Country of ref document: EP

Kind code of ref document: A2